Deeplex® Myc-TB: Cost-saving & cost-effective TB resistance detection
A recent study conducted in South Africa demonstrates the clinical value and cost-effectiveness of targeted next-generation sequencing for tuberculosis drug resistance testing, using Deeplex Myc-TB. It demonstrates that this approach improves the speed and accuracy of diagnosis, optimizes treatment management, reduces infectiousness and delivers measurable benefits for public health and healthcare costs…
New evidence supports Deeplex® Myc-TB as the reference method for enhanced drug-resistant TB detection
The World Health Organization (WHO) has published a new alarming report on the global rise of antibiotic resistance. According to its estimates, one-sixth of common bacterial infections worldwide were resistant to treatments in 2023, and the trend continues to worsen. Infectious diseases are a major global health concern accounting for a significant proportion of deaths worldwide. The emergence of antimicrobial…
GenoScreen and Clear Labs Announce the Launch of Clear Dx™ Deeplex® Myc-TB, an Automated Genomic Solution for Mycobacterium Characterization and TB Drug Resistance Detection
GenoScreen announces the launch of Clear Dx™ Deeplex® Myc-TB, developed in collaboration with Clear Labs.
This next-generation solution fully automates the widely adopted Deeplex® Myc-TB assay, enabling rapid and comprehensive detection of drug resistance…
Exciting news in leprosy detection and surveillance. Think positive!
Although considered an extinct calamity, leprosy is an infectious disease still present in more than hundred countries. Drug resistant strains of the bacterium responsible, Mycobacterium leprae, are emerging in several parts of the world, and transmission routes of the pathogen are not fully…
Seeking the source of tuberculosis drug resistance
A targeted deep sequencing assay identifies multidrugresistant tuberculosis strains responsible for silent outbreaks. An interview of Dr. Philip Supply, Senior Scientific Consultant at GenoScreen and Research Director at the CNRS…
Yes we can, end TB!
For over a decade, GenoScreen has been committed to the fight against tuberculosis (TB), one of the deadliest infectious diseases in the world. The company’s journey began with the groundbreaking development of MIRU-VNTR typing kits in 2013 which marked a turning point in TB research and control by enabling rapid and accurate identification of…